X4 Pharmaceuticals (XFOR) just posted its FY 2025 numbers with third quarter revenue of US$1.8 million, Basic EPS of US$0.69 loss, and a net loss of US$29.8 million, while trailing 12 month revenue stood at US$34.0 million with Basic EPS of US$5.90 loss and a net loss of US$95.1 million. Over the past few reported quarters, revenue has moved from US$0.6 million in the second quarter of 2024 to US$28.8 million in the first quarter of 2025, alongside EPS that swung from US$13.60 to US$0.04 and then back into loss territory. This provides investors with a view of how rapidly the P&L can shift around key product milestones. With one product now in Phase III and profitability still out of reach on a trailing basis, the focus this season is on whether the current revenue base can eventually support healthier margins.

With the headline figures on the table, the next step is to compare these results with the widely held narratives about X4 Pharmaceuticals's growth potential, risk profile, and path to better margins.

Revenue Swings Around One Big Quarter

• Across the last four reported quarters, revenue ranged from US$0.6 million in Q3 2024 to US$28.8 million in Q1 2025, with Q3 2025 coming in at US$1.8 million. This shows how dependent the top line currently is on a small number of events and early product sales rather than a steady run rate.
• What stands out for the bullish narrative that expects revenue to grow roughly 44% to 127% per year is that Q1 2025 briefly produced US$0.3 million of net income alongside US$28.8 million of revenue, yet the next two quarters went back to losses of US$25.7 million and US$29.8 million. This raises questions about how quickly those bulls see consistent profitability emerging even if sales do ramp.
  • Consensus and bullish views both lean on strong Phase III progress and international partnerships, but the trailing twelve month net loss of US$95.1 million shows the current business still relies heavily on funding rather than operating cash generation.
  • Bulls point to high confidence in trial outcomes and broader label potential, while these numbers show that any delay in turning those expectations into recurring revenue leaves the income statement firmly in loss making territory.

Bulls argue that recent revenue spikes are just the start of a larger growth story, so if you want to see how that full upside case is built out in detail, check out the 🐂 X4 Pharmaceuticals Bull Case.

Losses Persist Despite Revenue Growth

• Over the trailing twelve months to Q3 2025, X4 Pharmaceuticals booked US$34.0 million of revenue alongside a net loss of US$95.1 million and Basic EPS loss of US$5.90. Even the strongest single quarter, Q1 2025, only produced net income of US$0.3 million before the company moved back to losses above US$25 million in Q2 and Q3 2025.
• Bears argue that ongoing cash burn and dependence on a single drug keep profitability out of reach, and the data here gives them support because net losses in Q4 2024, Q2 2025 and Q3 2025 were US$39.8 million, US$25.7 million and US$29.8 million respectively, while analysts do not expect profits over the next three years even as revenue is forecast to grow around 70% a year.
  • Critics also highlight that analysts expect shares outstanding to rise about 7% per year for the next three years, which can further stretch per share results if losses remain large.
  • The combination of forecast high growth with continued losses and expected dilution lines up closely with the bearish concern that earnings per share may stay pressured even if the top line increases.

Skeptics focus on those repeated multi million dollar losses, so if you want the full cautious take built around that risk, it is worth reading through the 🐻 X4 Pharmaceuticals Bear Case.

Valuation Signals Versus Dilution Risk

• The shares trade on a P/S of 10.9x, which sits slightly below the US biotech industry average of 11.3x and below the peer average of 13.9x. This valuation sits alongside a trailing twelve month net loss of US$95.1 million and recent shareholder dilution that has been described as substantial.
• Consensus narrative suggests that relatively lower P/S and strong revenue growth forecasts help support the investment case, but the same analysis also flags material dilution and ongoing volatility. Investors weighing this up have to balance the more favorable sales based valuation against the fact that the company is unprofitable today and is not expected to reach profitability within the next three years.
  • Supporters point to potential revenue expansion from XOLREMDI and chronic neutropenia if approvals continue, while the risk summary calls out that recent dilution and price swings already reflect the market grappling with those uncertainties.
  • With the current share price at US$4.23 and analysts anchoring on a generic reference target of US$10.00, there is a clear gap between where the stock trades today and where some forecasts sit. Understanding how dilution and future losses fit into that gap is key.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for X4 Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and rewards feels hard to balance, now is the time to look through the numbers yourself and pressure test the bullish and bearish narratives against your own expectations by weighing up the 2 key rewards and 3 important warning signs.

See What Else Is Out There

X4 Pharmaceuticals shows large, recurring losses and heavy reliance on a single drug, which leaves earnings, dilution risk, and future stability looking uncertain for many investors.

If that concentration and volatility worries you, it is worth balancing your portfolio mix by checking companies in the 77 resilient stocks with low risk scores that aim for more resilient performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.